2022-RA-1115-ESGO Evaluation of cervical dysplasia with NOVAprep-miR-CERVIX

Introduction/Background Cervical cancer (CC) is one of the most common types and fourth leading cause cancer-related deaths in women. carcinogenesis multistep process cervical dysplasia development progression. Correct diagnostic effective therapy presents an important approach to reduce CC morbidity mortality. MicroRNAs epithelium cells are considered as promising markers dysplasia. MicroRNA-based test-systems can provide a helpful addition traditional techniques. Methodology NOVAprep-miR-CERVIX new test-system based on RT-qPCR analysis six miRNAs (miR-21–5p; miR-29b-3p; miR-145–5p; miR-451a-5p; miR-1246–5p miR-1290–3p) material smear. Test-system includes quality control enzymatic reaction efficacy. Machine learning random forest algorithm was applied for results evaluation. smear samples were obtained from 226 women: 114 normal 112 with high-grad intraepithelial lesion (HSIL) or carcinoma situ (CIS) result cytological Moreover, any HSIL/CIS diagnosis confirmed histologically. Results The 38 216 (17.8%) did not pass controls excluded analysis. Index (miR-CERVIX-I varied 0 1) calculated base miRNA remaining 178 samples. Difference miR-CERVIX-I statistically significant two groups formed cytological/histological (figure 1). Normal condition < 0.49) diagnosed sensitivity 79.2%, specificity 80.46%. HSIL 70.83%, 97.22% > 0.78). intermediate value (between 0.5 0.77) supposed reflect low-grade Conclusion be management test system complimentary standard methods.